PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast - David F. McDermott, MD - Redefining the Management of Advanced RCC: An Expert Tumor Board on Rational Selection, Sequencing, and Combination of Targeted Agents and Immunotherapy

David F. McDermott, MD - Redefining the Management of Advanced RCC: An Expert Tumor Board on Rational Selection, Sequencing, and Combination of Targeted Agents and Immunotherapy

07/26/19 • 67 min

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Go online to PeerView.com/FPP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, recorded from a live event at the 2019 American Society of Clinical Oncology Annual Meeting, a panel of kidney cancer experts offers case-centric discussion of key evidence that supports clinical decision-making through multiple lines of therapy in advanced RCC, as well as practical instruction on how to effectively and safely integrate novel targeted and immunotherapeutic strategies in an increasingly complex RCC treatment landscape. Upon completion of this activity, participants should be better able to: Summarize the latest evidence and ongoing investigations with novel approaches, including new multitargeted tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors, and combination therapies, in advanced renal cell carcinoma (RCC), Select optimal frontline treatment options among TKIs and combination approaches (dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors) for individual patients with advanced RCC based on relevant patient- and disease-related characteristics, including in the context of clinical trial enrollment, Recommend targeted agents and immune checkpoint inhibitors optimally to patients with pretreated advanced RCC through multiple lines of therapy, with considerations of prior treatment history and patient comorbidities, Employ effective strategies to prevent and/or manage treatment-related complications with multitargeted TKIs and immune checkpoint inhibitor therapy in patients with RCC.

Previous Episode

Elizabeth A. Stewart, MD - Advances in Medical Options for Uterine Fibroids and Endometriosis: Clinical Highlights From Montreal

Go online to PeerView.com/NNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in gynecology/obstetrics discusses emerging data on options for the treatment of endometriosis and uterine fibroids that were presented at the 5th Congress of the Society for Endometriosis and Uterine Disorders (SEUD 2019) in Montreal in May 2019. Upon completion of this activity, participants should be better able to: Discuss the latest clinical data on current and emerging treatment options for management of endometriosis, endometriosis-associated pain, and uterine fibroids, Employ recent evidence on new and established treatment approaches for individualized therapeutic management of patients with endometriosis and uterine fibroids.

Next Episode

Robert Dreicer, MD, MS, MACP, FASCO - New Concepts in Prostate Cancer Care: What Oncologists Need to Know to Optimize Patient Outcomes

Go online to PeerView.com/NXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape for prostate cancer has evolved rapidly in recent years, and research endeavors continue to expand treatment options, with significant implications for patients with early-stage and advanced disease. In addition to the approval of multiple second-generation anti-androgen therapies in nonmetastatic castration-resistant and metastatic hormone-sensitive prostate cancer, current clinical trials are investigating novel targeted therapies, immunotherapies, and combination approaches in different disease settings. When managing patients with prostate cancer, clinicians must consider established, newly approved, and emerging therapies throughout the disease continuum, as well as individual patient-, tumor-, and treatment-related factors. Questions that frequently arise include: What is the impact of using anti-androgen therapies earlier in the treatment plan? What is the ideal way to sequence therapies in different disease settings? How should therapy be personalized to ensure that each patient with prostate cancer receives the right treatment? Answers to these and other thought-provoking queries are provided by a panel of prostate cancer experts in this PeerView Talks CME-certified on-demand activity based on a recent live symposium at the American Society of Clinical Oncology Annual Meeting 2019 (ASCO 2019) in Chicago, Illinois. Utilizing an innovative educational design, the experts relate engaging patient stories and link them to practical clinical considerations, enabling learners to better connect evidence to everyday practice. Upon completion of this activity, participants should be better able to: Discuss the clinical evidence, latest guidelines, and expert recommendations for selection and sequencing of hormonal, anti-androgen, cytotoxic, bone-directed, molecularly targeted, and other therapies throughout the disease continuum for patients with hormone-naïve, hormone-sensitive, or castration-resistant, nonmetastatic, and metastatic prostate cancer, Develop personalized, evidence-based treatment plans for patients with early-stage and advanced prostate cancer with considerations of tumor-, patient-, and treatment-related factors, Summarize current and planned clinical trials assessing novel strategies with potential to improve outcomes in different prostate cancer settings.